Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis
Wednesday, June 03, 2026Cumberland Pharmaceuticals Inc Nasdaq CPIX a specialty pharmaceutical company focused on developing new products for rare diseases and Vanderbilt Health today announce data from a Phase a clinical trial
Gilead’s Livdelzi® (Seladelpar) Delivers Statistically Significant Composite ALP Normalization in Phase 3 IDEAL Trial in Primary Biliary Cholangitis (PBC)
Wednesday, June 03, 2026Gilead Sciences Inc Nasdaq GILD today announced positive results from a Phase study in people with primary biliary cholangitis PBC showing that treatment with Livdelzi seladelpar led to significantly more patients
Lundbeck Partners with Cradle to Discover and Optimize Brain Disorder Treatments
Wednesday, June 03, 2026H Lundbeck AS Lundbeck a global biopharmaceutical company focused exclusively on brain health and Cradle a leading AI platform for protein engineering today announced a partnership to help Lundbeck discover and optimize
FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting
Tuesday, June 02, 2026Roche announced today that the United States US Food and Drug Administration FDA has accepted the companys New Drug Application NDA under Priority Review for giredestrant an investigational oral selective
Decoy Therapeutics Partners with hVIVO to Advance Lead D-MAV™ Candidate into the Clinic
Tuesday, June 02, 2026Decoy Therapeutics Inc a preclinicalstage biotechnology company pioneering a new category of antivirals today announced the execution of a strategic development initiative designed to support
Sino Biological’s Cell-Free Protein Synthesis Supports Tencent AI for Life Sciences Lab’s Protein Design Study Published in Nature Communications
Tuesday, June 02, 2026Sino Biological Inc Shenzhen Stock Exchange SZ has announced that its gene synthesis and cellfree protein expression workflow was used in a recent study by Tencent AI for Life Sciences Lab published in Nature
T-CURX Acquires Pantherna Therapeutics to Accelerate Clinical Translation of its Non-Viral In Vivo CAR-T Strategies
Monday, June 01, 2026Leading CART company TCURX announces the signing of a definitive agreement for the acquisition of Pantherna Therapeutics a German biotechnology company specializing in mRNA engineering and lipid nanoparticle LNP
Alaw Therapeutics Announces Two Major Pipeline Milestones Advancing Brain-Penetrant CDK Oncology Programs
Saturday, May 30, 2026Alaw Therapeutics Inc Alaw a clinicalstage biotechnology company developing precision oncology therapeutics designed to control oncogenic proliferation tumor survival and therapeutic resistance
IMFINZI® (durvalumab) approved in the US in first and only immunotherapy combination for patients with BCG-naïve, high-risk non-muscle-invasive bladder cancer
Friday, May 29, 2026AstraZenecas IMFINZI durvalumab in combination with Bacillus CalmetteGurin BCG induction and maintenance therapy has been approved in the US for the treatment of adult patients with BCGnave highrisk nonmuscleinvasive bladder cancer NMIBC
Adcendo ApS Announces Clinical Collaboration and Supply Agreement with MSD to Evaluate ADCE-T02 in Combination with KEYTRUDA® (Pembrolizumab) in a Phase Ib Study in Patients with Advanced Solid Tumors
Wednesday, May 27, 2026Adcendo ApS Adcendo a biotech company focused on the development of first and bestinclass antibodydrug conjugates ADCs for the treatment of cancers with high unmet medical need today announced that it has entered
